ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.Clinical & developmental immunology · 2011Trial
- Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2008Trial
- Polyunsaturated Fatty Acid-Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism.Cancer research · 2023Article
- Genome-wide association study of serum tumor markers in Southern Chinese Han population.BMC cancer · 2022Article
- Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges.Frontiers in cell and developmental biology · 2021Review
- Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients.Clinical and experimental hepatology · 2020Article
- Article
- Cancer biomarkers for targeted therapy.Biomarker research · 2019Article
- Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular CarcinomaAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Human vaccines & immunotherapeutics · 2017Review
- Spontaneous regression of hepatocellular carcinoma: A mini-review.World journal of gastroenterology · 2017Review
- Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma.Gut and liver · 2017Article
- Lessons learned from cancer vaccine trials and target antigen choice.Cancer immunology, immunotherapy : CII · 2016Review
- Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.Journal for immunotherapy of cancer · 2015Article
- Immunotherapy of hepatocellular carcinoma.Hepatic oncology · 2014Review
- Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.Journal of translational medicine · 2014Article
- Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.Journal for immunotherapy of cancer · 2013Article
- Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.Oncoimmunology · 2012Article
- Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Oncoimmunology · 2012Article
- Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.Oncoimmunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and is often diagnosed at an advanced stage. We have investigated alpha-fetoprotein (AFP) as a tumor-associated antigen for HCC. We identified major histocompatibility complex class I-restricted peptide epitopes derived from AFP and studied CD8 T-cell responses in vivo and in vitro in ongoing immunotherapy studies. Helper T cells are of critical importance in shaping the immune response; therefore, we investigated the frequency and function of AFP-specific CD4 T cells in the general population and among HCC patients. CD4 T-cell responses were assessed by direct ex vivo multicytokine enzyme-linked immunospot assay and by measurement of cytokine levels using a multicytokine assay. Our analysis indicates that healthy donors have very low frequencies of AFP-specific CD4 T-cell responses, which are of TH1 type, detectable ex vivo. In contrast, these T cells were either reduced or eliminated in HCC patients at advanced stages of disease. To better activate these cells, we compared the stimulatory capacity of both AFP protein-fed and AdVhAFP-engineered dendritic cells (DC). Healthy donors have CD4 T-cell responses, which were activated in response to AFP protein-fed DC whereas HCC patients do not demonstrate significant responses to AFP protein. AdVhAFP-transduced DC were capable of activating higher frequency TH1 CD4 responses to AFP in both healthy donors and AFP-positive HCC patients. Importantly, CD4 T-cell cytokine expression profiles were skewed towards interleukin-2 and interferon-gamma production when activated by adenovirally engineered DC, which has therapeutic implications for vaccination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.